Welcome to our dedicated page for Larimar Therapeutics news (Ticker: LRMR), a resource for investors and traders seeking the latest updates and insights on Larimar Therapeutics stock.
Larimar Therapeutics, Inc. (NASDAQ: LRMR) is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, with its lead compound, nomlabofusp, in development as a potential treatment for Friedreich’s ataxia (FA). The Larimar news feed on Stock Titan aggregates the company’s press releases and related coverage so readers can follow key milestones in this rare disease program.
News about Larimar frequently centers on clinical data updates from the ongoing long-term open-label and open-label extension studies of nomlabofusp in FA. The company has reported increases in skin frataxin (FXN) levels with daily subcutaneous dosing, directional improvements in clinical outcome measures such as mFARS, FARS-ADL, 9-Hole Peg Test, and Modified Fatigue Impact Scale, and long-term safety observations including injection site reactions and anaphylaxis events. Larimar also publishes nonclinical findings that describe the mechanism of action and pharmacology of nomlabofusp as an FXN protein replacement therapy.
Another major category of LRMR news involves regulatory interactions and timelines. Larimar has disclosed written recommendations from the U.S. Food and Drug Administration on the safety database needed for its Biologics License Application and the agency’s openness to using skin FXN concentrations as a reasonably likely surrogate endpoint for an accelerated approval pathway. The company regularly issues press releases on these regulatory updates, its participation in the START pilot program, and its targeted timing for a BLA submission seeking accelerated approval.
Investors and followers will also see financial results and capital markets announcements, including quarterly operating and financial updates, underwritten public offerings of common stock, and the use of proceeds to fund nomlabofusp development and other pipeline plans. For a consolidated view of LRMR-related developments—spanning clinical, regulatory, and financing events—this news page provides an organized stream of Larimar’s own disclosures and market-facing communications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.